| Name | Title | Contact Details |
|---|
Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies. With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments that make a real difference in the lives of patients. We also put great focus on being good corporate citizens. Our commitment to corporate citizenship extends to patient education and support programs, giving back to the communities in which we operate, promoting and advancing science education, and operating in a sustainable manner. These cultural imperatives are directly incorporated into our business activities.
Plexxikon is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.